The challenges highlight the difficulties that bailed-out Banco Espirito Santo and its successor Novo Banco face as they try to recover some of the family's massive debts.» Read More
Shares of Dow component Merck rare getting a nice little shot in the arm this morning on an upgrade by Dr. Tim Anderson at Sanford C. Bernstein. He's putting an "Outperform" or "Buy" rating on MRK and raising his target price three bucks to $30.
Only on a day like today when it's wall-to-wall Madoff coverage would a $47 billion deal, the second $40-billion-plus deal to be done in four days, struggle to get some airtime.
When a press release crosses the wires or pops into the inbox from a Dow component announcing positive late-stage test results on a cancer drug, you rush to get the headlines on the air as quickly as possible.
The Biotechnology Industry Organization just announced that Sir Elton will be the keynote speaker at the 2009 BIO International Convention in Atlanta, the superstar's American hometown.
On my Thomson Reuters screen I have the stock quotes of a few dozen of the biopharma companies I cover. Lately, when I glance over at it, there's been a lot of red. With today's market rally, there's a whole lotta green. And that's why the quote in red for Genentech kind of sticks out like a sore thumb.
They may have the same name, but America's oldest teenager Dick Clark and Merck's Chairman and CEO Dick Clark appear to have little else in common. One loves the camera, the other not so much.
New Jersey, where I live and work, is known as "The World's Medicine Chest" or "The Silicon Valley of Pharma."
Yeah, "Deal Or No Deal" has become a bit of a tired cliche, but I think it's totally appropriate in the context of the latest salvo in the Roche-Genentech takeover battle.
Japan and Januvia. No, it's not a country—not even a fictional one—even though it sounds like "Genovia" in "The Princess Diaries." It's a diabetes drug from Merck.
As Pfizer Chairman and CEO Jeff Kindler represents at the White House Healthcare Summit today and tries to make the industry's case against government price controls on prescription drugs, a couple of prominent industry analysts are giving him a little something to smile about.
Hartford Financial Services Group is in talks to sell most of its life insurance unit to Canada's Sun Life Financial, according to the Wall Street Journal.
Forget about mergers and acquisitions (M & A). Think about partnerships and acquisitions or what Leerink Swann, which specializes in healthcare stock coverage, is calling "P & A."
American International Group should be allowed to go bankrupt because keeping it and other sick financials alive on government support risks ruining the US economy, legendary investor Jim Rogers told CNBC Tuesday.
The morning after Genentech's big investor meeting shares of the Swiss drugmaker Roche rebounded in overseas trading and the American Despository Receipts that trade over-the-counter here in the States are following suit.
By easing the terms of its $150 billion rescue package for the American International Group, the government is trying to buy time for the financial conglomerate to slim down and reinvent itself as a simple property and casualty insurer, with a new name, new faces in the boardroom and perhaps an initial public offering in its future.
No doubt the president’s hopes for this country are noble, but right now they’re killing the markets.
The Dow Jones Industrial Average hit its lowest level in 12 years, slipping below 7,000, then 6,900 and then 6,800, as another bailout of insurance giant AIG stirred fear about the stability of the financial system.
The Dow Jones Industrial Average opened at its lowest level in 12 years, slipping below 7,000 as investors grew increasingly skittish over the state of the stock market amid the wave of government bailouts.
Today was really ugly for biotech. The only large-cap sector stock to trade higher--and significantly--was Genentech because it's being bolstered by Roche's bond sale and increasing speculation the Swiss drugmaker is gonna have to raise its bid for DNA.
Plus, Cramer talks insurers, health care and President Obama's Medicare changes.
Get the best of CNBC in your inbox